Amphastar Pharmaceuticals, Inc. (AMPH)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Jun 20, 2025

$24.56

P/E Ratio

8.91

Market Cap

$1.16B

Description
Add to research
View more

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Metrics
Add to research
View more

Overview

  • HQRancho Cucamonga, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerAMPH
  • Price$24.56-3.08%

Trading Information

  • Market cap$1.16B
  • Float73.36%
  • Average Daily Volume (1m)497,141
  • Average Daily Volume (3m)569,047
  • EPS$2.93

Company

  • Revenue$730.66M
  • Rev growth (1yr)-0.76%
  • Net income$25.29M
  • Gross margin48.13%
  • EBITDA margin30.79%
  • EBITDA$52.50M
  • EV$1.86B
  • EV/Revenue2.54
  • P/E8.91
  • P/S1.68
  • P/B1.56
  • Debt/Equity86.86
Documents
Add to research
View more